Vcoderz Community
We create websites that have it all, beauty & brains
Lebanon Web Design & Development - Coddict
 

Go Back   Vcoderz Community > Community Forums > Health & Science Room

Notices

Health & Science Room « Everything related to health, safety and science »

Reply
 
Share Thread Tools Search this Thread
Old 04-03-2008   #1
TAREK®
~ Golden Boy ~
 
TAREK®'s Avatar
 
Last Online: 06-14-2013
Join Date: Oct 2007
Posts: 11,464
Thanks: 11,906
Thanked 5,073 Times in 3,294 Posts
Groans: 190
Groaned at 82 Times in 72 Posts
Default New Anti-Cancer Drug for Aggressive Brain Tumors

Researchers are constantly trying to find new drugs or forms of therapy that can be used to treat cancer. Quite often when a possible treatment is discovered, being allowed to test a drug or other experimental cancer treatment at a clinical level is difficult. For example, after an anti-carcinogenic drug has been thoroughly tested at the experimental level it is necessary to test it in humans to analyze factors such as the drug’s anti-tumor activity, its ability to interact with a specific target, and to discover which patients are more likely to benefit from the drug. These types of early clinical trials are the key in the successful implementation of effective anti-tumor drugs and therapies.

One such study was done to treat a small group of glioblastoma patients with an experimental drug called rapamycin since they needed to undergo surgery because their glioblastoma tumors returned. Glioblastomas are aggressive brain tumors that are very invasive and exhibit rapid metastasis. Currently chemotherapy and surgery are not effective treatments for this type of cancer and in most cases, the tumors often return after treatment. This has caused researchers to look for alternative forms of treatment for glioblastomas that include anti-tumor drugs. An interesting discovery about glioblastoma cases is that approximately 40% of patients who develop glioblastomas have a gene called PTEN that becomes inactive. PTEN is a tumor suppressor gene that sensitizes cancer cells to drugs called mTOR inhibitors when it is inactivated. mTOR is a protein that plays a role in cell growth and proliferation. Rapamycin, also called Sirolimus, is an mTOR inhibitor and the anti-carcinogenic and well as immunosuppressive affects of these types of drugs are currently being evaluated.


For this study, 15 patients whose glioblastoma tumors returned were treated with different amounts of rapamycin one week before and after surgery. Each of these patients had tumors that did not express the PTEN gene and if the tumor appeared to be progressing after surgery the rapamycin treatment was discontinued. The purpose of this study was to determine if the drug could inhibit tumor growth and if so, at what concentration. In addition the researchers were hoping to reveal which patients were more likely to respond to rapamycin treatment.

The results of this study showed that the rate of tumor cell proliferation decreased in 7 of the 15 patients treated with rapamycin after surgery, and severe toxicity did not occur in most of the patients. The reduction of tumor cell proliferation was directly correlated to the inhibition of the mTOR protein. Scans that were obtained from 2 patients even showed signs that the tumor mass was decreasing. Unfortunately, when tumor cells that reacted to rapamycin in patients were tested in a laboratory setting, the cells no longer responded to rapamycin treatment. This appeared to be due to the drug’s inability to penetrate the tumor ex vivo. In addition, the treatment of rapamycin led to the activation of a protein called Akt in some patients, which decreased the time period between surgery and a reoccurrence of their tumor.

These results showed that although rapamycin caused a reduction of tumor cell proliferation in some glioblastoma patients, in others it activated a second protein that accelerated the progression of the disease. This strengthens the point that these types of studies are essential. The side effects of this drug in some patients is life threatening so it is important to analyze the clinical effects from a small group of selected patients before the drug is distributed on a large scale level or in clinics nationwide.

Source: brainblogger.com


TAREK® is offline   Reply With Quote
The Following User Says Thank You to TAREK® For This Useful Post:
AnGe|ic (04-03-2008)
Old 04-03-2008   #2
mr_j
Community Moderator
 
mr_j's Avatar
 
Last Online: 4 Days Ago
Join Date: Oct 2007
Posts: 2,519
Thanks: 3,021
Thanked 2,076 Times in 1,156 Posts
Groans: 7
Groaned at 34 Times in 27 Posts
Default Re: New Anti-Cancer Drug for Aggressive Brain Tumors

that's all well and good but I have a question:
for years we've been hearing about cures for cancer and the last time was the previous year when this wise lebanese dude had done researches on mice and it all went well
my question is how come everytime things like that are discovered we never hear about it again? this is getting hopeless
mr_j is offline   Reply With Quote
Reply

  Vcoderz Community > Community Forums > Health & Science Room

Tags
aggressive, anticancer, brain, drug, tumors



Currently Active Users Viewing This Thread: 1 (0 members and 1 guests)
 
Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT +1. The time now is 10:57 PM.


Lebanon web design and development
Powered by vBulletin® Version 3.8.3
Copyright ©2000 - 2019, Jelsoft Enterprises Ltd.
Ad Management plugin by RedTyger
Share